Real world study for adverse reactions of apatinib in the treatment of patients with advanced malignant solid tumor in Jiangxi province

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019193

Enrollment

Unknown

Registered

2018-10-30

Start date

2018-10-30

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

Case series:apatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Aged 18 years or older, male or female; 2. Patients with advanced malignant solid tumor diagnosed by pathology or histology (including but not limited to advanced gastric cancer, lung cancer, liver cancer, breast cancer, cervical cancer, ovarian cancer, etc.); 3. Voluntarily join the study and sign the informed consent; 4. The researcher thinks it can benefit.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with apatinib contraindications are excluded; 3. Doctors consider it not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Adverse events;	—

Contacts

Public ContactXiao Jiansheng

the First Affiliated Hospital of Nanchang University

15211462451@163.com+86 13517911330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026